ArticleJournal for immunotherapy of cancer2025

Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer.

Ana C Garrido-Castro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.